Windward Bio secured $165 million to advance long-acting antibody programs across asthma and COPD, with additional development planned for respiratory and dermatological indications. The financing is designed to support clinical trials as the company targets dosing advantages over existing biologics, aiming to convert pipeline momentum into near-term trial progress.